chiron

11/01/1999 - "Two hundred sixty-six eyes of 150 patients were subjected to PRK with the Chiron Technolas Keracor 117C for the correction of myopia and astigmatism. "
11/01/1999 - "LASIK with the Chiron-Technolas Keracor 116 excimer laser was effective for correction of myopic astigmatism, with good stability after 3 months. "
07/01/2004 - "This prospective study included 28 eyes of 21 patients with mixed astigmatism who had bitoric LASIK using the Hansatome microkeratome (Bausch & Lomb Surgical) and the Chiron Technolas 217 excimer laser (Bausch & Lomb Surgical). "
03/01/2001 - "Patients with myopia and myopic astigmatism (N=2,972; refraction from -1.25 to -15.50 D) were treated with the Nidek EC-5000 excimer laser, using the Chiron Vision HT-230 Hansatome microkeratome. "
11/01/1997 - "We retrospectively studied the results of our initial 83 eyes with myopia ranging from -1.13 to -7.25 diopters (D) and astigmatism of no more than 4.00 D that underwent LASIK with the Chiron Technolas Keracor 117 PlanoScan. "

03/01/1996 - "When inserting the Chiron-Adatomed myopia IOL, we avoided putting pressure on the crystalline lens with the spatula. "
09/01/1998 - "In 12 of 20 eyes, the homoplastic button, which had parallel faces and was devoid of any dioptric power, was treated refractively on its stromal face with a Chiron Keracor 116 excimer laser to correct the axial and/or induced myopia present due to the weakened cornea. "
03/01/1997 - "Using an eyebank eye model, we performed automated lamellar keratoplasty to theoretically correct 10.00 diopters (D) of myopia using the Automated Corneal Shaper, manufactured by Chiron, Inc. "
11/01/1999 - "Two hundred sixty-six eyes of 150 patients were subjected to PRK with the Chiron Technolas Keracor 117C for the correction of myopia and astigmatism. "
02/01/2001 - "In this retrospective study, the records of patients who had LASIK for myopia greater than -6.0 diopters (D) using the Chiron Automated Corneal Shaper and the Schwind Keratome-F excimer laser were reviewed. "

04/01/1997 - "Over a year after approval of Chiron Vision's Vitrasert eye implant for treating CMV retinitis, concerns about the safety and efficacy of the implant can be better addressed. "
07/01/1995 - "Chiron Vision files FDA application to market intraocular implant for CMV retinitis. "
09/01/1995 - "Chiron Corporation has joined ranks with Hoffman-La Roche to market a new drug, a ganciclovir implant inserted into the eye, for treatment of CMV retinitis. "
07/01/1995 - "Chiron Corporation and Hoffman-LaRoche announced a filing of a New Drug Application with the Food and Drug Administration (FDA) to market Vitrasert, its intraocular implant which delivers ganciclovir directly to the eye for treatment of CMV retinitis. "
09/01/1995 - "Approvals are being sought for stavudine's use in HIV-positive adults with CD4 counts between 50 and 500 who have been treated with at least 24 months of zidovudine; Biaxin's use for prevention of Mycobacterium avium complex in patients with advanced HIV infection; and Chiron's method of treating CMV retinitis."

07/01/1999 - "Fourteen patients aged 7 to 12 years with myopic anisometropia and amblyopia had LASIK in the more myopic eye (14 eyes) using the Chiron Automatic Corneal Shaper and the Chiron-Technolas Keracor 116 excimer laser. "
03/01/2001 - "LASIK with the Nidek EC-5000 excimer laser and the Hansatome Chiron Vision HT-230 microkeratome, together with occlusion and orthoptic therapy for pediatric correction of spherical anisometropia, may be an effective procedure that facilitates increased visual acuity and improved binocular vision. "

08/01/1998 - "A large, randomized, placebo-controlled clinical trial in Italy on two three-component pertussis vaccines, given as DTaP in infancy, one manufactured by SmithKline and Beecham (SB) and one by Chiron Biocine (CB), found each vaccine to be 84% efficacious through the average age of 24 months. "
01/01/1997 - "Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers."
01/01/1997 - "This is a randomized blinded trial evaluating the safety and immunogenicity of the recombinant aPDT vaccine (C-aPDT, Chiron/Biocine) in 2000 infant recipients compared with 498 controls who received whole cell diphtheria-pertussis-tetanus (wDPT; Connaught) vaccine at 2, 4 and 6 months of age. "
01/01/1997 - "To evaluate the safety and immunogenicity of the recombinant acellular pertussis-diphtheria-tetanus (aPDT) vaccine (C-aPDT, Chiron/Biocine). "
11/01/2003 - "Children had received 1 of 2 three-component acellular pertussis vaccines produced by 2 manufacturers (diphtheria-tetanus-acellular pertussis from, Chiron Biocine [DTaP CB]; DTaP from SmithKline Beecham [DTaP SB]) or a diphtheria-tetanus vaccine only (DT; Chiron Biocine). "